Gilead Sciences Drug Patent Portfolio
Gilead Sciences owns 1 orange book drug protected by 33 US patents Given below is the list of Gilead Sciences's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8598185 | Unitary pharmaceutical dosage form | 28 Apr, 2029 | Active |
| US9018192 | Unitary pharmaceutical dosage form | 13 Jun, 2026 | Active |
| US9545414 | Unitary pharmaceutical dosage form | 13 Jun, 2026 | Active |
| US8716264 | Compositions and methods for combination antiviral therapy | 03 Jul, 2024 | Expired |
| US8592397 | Compositions and methods for combination antiviral therapy | 13 Jan, 2024 | Expired |
| US8716264 | Compositions and methods for combination antiviral therapy | 13 Jan, 2024 | Expired |
| US9457036 | Compositions and methods for combination antiviral therapy | 13 Jan, 2024 | Expired |
| US9744181 | Compositions and methods for combination antiviral therapy | 13 Jan, 2024 | Expired |
| US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers | 09 Sep, 2021 | Expired |
| US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | 04 May, 2021 | Expired |
| US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers | 09 Mar, 2021 | Expired |
| US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | 04 Nov, 2020 | Expired |
| US6639071 | Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one | 14 Aug, 2018 | Expired |
| US6939964 | Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one | 20 Jul, 2018 | Expired |
| US6639071 | Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one | 14 Feb, 2018 | Expired |
| US5922695 | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability | 25 Jan, 2018 | Expired |
| US5935946 | Nucleotide analog composition and synthesis method | 25 Jan, 2018 | Expired |
| US5977089 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability | 25 Jan, 2018 | Expired |
| US6043230 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability | 25 Jan, 2018 | Expired |
| US6939964 | Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one | 20 Jan, 2018 | Expired |
| US5914331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | 02 Jan, 2018 | Expired |
| US5922695 | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability | 25 Jul, 2017 | Expired |
| US5935946 | Nucleotide analog composition and synthesis method | 25 Jul, 2017 | Expired |
| US5977089 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability | 25 Jul, 2017 | Expired |
| US6043230 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability | 25 Jul, 2017 | Expired |
| US5914331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | 02 Jul, 2017 | Expired |
| US5814639 | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds | 29 Mar, 2016 | Expired |
| US5814639 | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds | 29 Sep, 2015 | Expired |
| US5663169 | Benzoxazinones as inhibitors of HIV reverse transcriptase | 02 Mar, 2015 | Expired |
| US5663169 | Benzoxazinones as inhibitors of HIV reverse transcriptase | 02 Sep, 2014 | Expired |
| US5519021 | Benzoxazinones as inhibitors of HIV reverse transcriptase | 21 Nov, 2013 | Expired |
| US5519021 | Benzoxazinones as inhibitors of HIV reverse transcriptase | 21 May, 2013 | Expired |
| US5811423 | Benzoxazinones as inhibitors of HIV reverse transcriptase | 07 Aug, 2012 | Expired |
Latest Legal Activities on Gilead Sciences's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Gilead Sciences.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Jul, 2024 | US9545414 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Oct, 2022 | US9018192 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 May, 2021 | US8598185 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 May, 2021 | US8592397 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Feb, 2021 | US9744181 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 02 Jul, 2020 | US9545414 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 Oct, 2018 | US9018192 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 29 Aug, 2017 | US9744181 |
|
Recordation of Patent Grant Mailed
Critical
| 29 Aug, 2017 | US9744181 |
|
Email Notification
Critical
| 10 Aug, 2017 | US9744181 |
|
Issue Notification Mailed
Critical
| 09 Aug, 2017 | US9744181 |
|
Application Is Considered Ready for Issue
Critical
| 02 Aug, 2017 | US9744181 |
| Dispatch to FDC | 02 Aug, 2017 | US9744181 |
|
Email Notification
Critical
| 01 Aug, 2017 | US9744181 |
| Mailing Corrected Notice of Allowability | 01 Aug, 2017 | US9744181 |
Gilead Sciences's Drug Patent Litigations
Gilead Sciences's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 05, 2001, against patent number US6642245. The petitioner , challenged the validity of this patent, with DIONNE as the respondent. Click below to track the latest information on how companies are challenging Gilead Sciences's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US5935946 | June, 2014 |
Terminated-Denied
(17 Dec, 2014)
| Gilead Sciences, Inc. | MYLAN PHARMACEUTICALS INC. |
| US5922695 | June, 2014 |
Terminated-Denied
(09 Dec, 2014)
| Gilead Sciences, Inc. | Mylan Pharmaceuticals Inc. |
| US5977089 | June, 2014 |
Terminated-Denied
(09 Dec, 2014)
| Gilead Sciences, Inc. | Mylan Pharmaceuticals Inc. |
| US6043230 | June, 2014 |
Terminated-Denied
(09 Dec, 2014)
| Gilead Sciences, Inc. | Mylan Pharmaceuticals Inc. |
| US6703396 | April, 2002 |
Decision
(04 Apr, 2002)
| DIONNE | |
| US6642245 | July, 2001 |
Decision
(05 Jul, 2001)
| DIONNE | |
Gilead Sciences Drug Patents' Oppositions Filed in EPO
Gilead Sciences drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 13, 2009, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP04701819A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP11167101A | Dec, 2015 | Hetero Drugs Ltd. | Revoked |
| EP11167101A | Dec, 2015 | Sandoz AG | Revoked |
| EP11167101A | Dec, 2015 | Accord Healthcare Ltd | Revoked |
| EP11167101A | Dec, 2015 | KELTIE LLP | Revoked |
| EP11167101A | Dec, 2015 | Strawman Limited | Revoked |
| EP06773194A | Oct, 2009 | Teva Pharmaceutical Industries Ltd. | Revoked |
| EP04701819A | Mar, 2009 | Generics [UK] Limited | Revoked |
| EP04701819A | Mar, 2009 | Teva Pharmaceutical Industries LTD. | Revoked |
Gilead Sciences's Family Patents
Gilead Sciences drugs have patent protection in a total of 31 countries. It's US patent count contributes only to 21.3% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Gilead Sciences Drug List
Given below is the complete list of Gilead Sciences's drugs and the patents protecting them.
1. Atripla
Atripla is protected by 33 patents, out of which 30 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8598185 | Unitary pharmaceutical dosage form |
28 Apr, 2029
(3 years from now)
| Active |
| US9018192 | Unitary pharmaceutical dosage form |
13 Jun, 2026
(1 year, 30 days from now)
| Active |
| US9545414 | Unitary pharmaceutical dosage form |
13 Jun, 2026
(1 year, 30 days from now)
| Active |
| US8716264
(Pediatric)
| Compositions and methods for combination antiviral therapy |
03 Jul, 2024
(10 months ago)
| Expired |
| US8592397 | Compositions and methods for combination antiviral therapy |
13 Jan, 2024
(1 year, 3 months ago)
| Expired |
| US8716264 | Compositions and methods for combination antiviral therapy |
13 Jan, 2024
(1 year, 3 months ago)
| Expired |
| US9457036 | Compositions and methods for combination antiviral therapy |
13 Jan, 2024
(1 year, 3 months ago)
| Expired |
| US9744181 | Compositions and methods for combination antiviral therapy |
13 Jan, 2024
(1 year, 3 months ago)
| Expired |
| US6703396
(Pediatric)
| Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
09 Sep, 2021
(3 years ago)
| Expired |
| US6642245
(Pediatric)
| Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
04 May, 2021
(4 years ago)
| Expired |
| US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
09 Mar, 2021
(4 years ago)
| Expired |
| US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
04 Nov, 2020
(4 years ago)
| Expired |
| US6639071
(Pediatric)
| Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
14 Aug, 2018
(6 years ago)
| Expired |
| US6939964
(Pediatric)
| Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
20 Jul, 2018
(6 years ago)
| Expired |
| US6639071 | Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
14 Feb, 2018
(7 years ago)
| Expired |
| US5922695
(Pediatric)
| Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
25 Jan, 2018
(7 years ago)
| Expired |
| US5935946
(Pediatric)
| Nucleotide analog composition and synthesis method |
25 Jan, 2018
(7 years ago)
| Expired |
| US5977089
(Pediatric)
| Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
25 Jan, 2018
(7 years ago)
| Expired |
| US6043230
(Pediatric)
| Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
25 Jan, 2018
(7 years ago)
| Expired |
| US6939964 | Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one |
20 Jan, 2018
(7 years ago)
| Expired |
| US5914331
(Pediatric)
| Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
02 Jan, 2018
(7 years ago)
| Expired |
| US5922695 | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
25 Jul, 2017
(7 years ago)
| Expired |
| US5935946 | Nucleotide analog composition and synthesis method |
25 Jul, 2017
(7 years ago)
| Expired |
| US5977089 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
25 Jul, 2017
(7 years ago)
| Expired |
| US6043230 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
25 Jul, 2017
(7 years ago)
| Expired |
| US5914331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
02 Jul, 2017
(7 years ago)
| Expired |
| US5814639
(Pediatric)
| Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
29 Mar, 2016
(9 years ago)
| Expired |
| US5814639 | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
29 Sep, 2015
(9 years ago)
| Expired |
| US5663169
(Pediatric)
| Benzoxazinones as inhibitors of HIV reverse transcriptase |
02 Mar, 2015
(10 years ago)
| Expired |
| US5663169 | Benzoxazinones as inhibitors of HIV reverse transcriptase |
02 Sep, 2014
(10 years ago)
| Expired |
| US5519021
(Pediatric)
| Benzoxazinones as inhibitors of HIV reverse transcriptase |
21 Nov, 2013
(11 years ago)
| Expired |
| US5519021 | Benzoxazinones as inhibitors of HIV reverse transcriptase |
21 May, 2013
(11 years ago)
| Expired |
| US5811423 | Benzoxazinones as inhibitors of HIV reverse transcriptase |
07 Aug, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Atripla's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List